Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
Goethe University Frankfurt · Uppsala University · +7 more institutions
Abstract
BACKGROUND: Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. METHODS AND RESULTS: The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. Compared with warfarin, dabigatran 110 mg twice a day was associated with a lower risk of major bleeding (2.87% versus 3.57%; P=0.002), whereas dabigatran 150 mg twice a day was associated with a similar risk of major bleeding…
Citation impact
- FWCI
- 91.06
- Percentile
- 100%
- References
- 16
Authors
16- JWJohn W. EikelboomCorresponding
Goethe University Frankfurt, Uppsala University, Uppsala University Hospital, Lankenau Institute for Medical Research, Mario Negri Institute for Pharmacological Research, Henry Ford Hospital, Wilhelminen Hospital, Boehringer Ingelheim (France), University of Duisburg-Essen
- LWLars Wallentin
Goethe University Frankfurt, Uppsala University, Uppsala University Hospital, Lankenau Institute for Medical Research, Mario Negri Institute for Pharmacological Research, Henry Ford Hospital, Wilhelminen Hospital, Boehringer Ingelheim (France), University of Duisburg-Essen
- SJStuart J. Connolly
Goethe University Frankfurt, Uppsala University, Uppsala University Hospital, Lankenau Institute for Medical Research, Mario Negri Institute for Pharmacological Research, Henry Ford Hospital, Wilhelminen Hospital, Boehringer Ingelheim (France), University of Duisburg-Essen
- MEMike Ezekowitz
Goethe University Frankfurt, Uppsala University, Uppsala University Hospital, Lankenau Institute for Medical Research, Mario Negri Institute for Pharmacological Research, Henry Ford Hospital, Wilhelminen Hospital, Boehringer Ingelheim (France), University of Duisburg-Essen
- JSJeff S. Healey
Goethe University Frankfurt, Uppsala University, Uppsala University Hospital, Lankenau Institute for Medical Research, Mario Negri Institute for Pharmacological Research, Henry Ford Hospital, Wilhelminen Hospital, Boehringer Ingelheim (France), University of Duisburg-Essen
Topics & keywords
- Medicine
- Dabigatran
- Warfarin
- Atrial fibrillation
- Stroke (engine)
- Randomized controlled trial
- Internal medicine
- Anticoagulant
- Good health and well-being